GAP T cells

GAP T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target Glypican-3 (GPC3), a cell-surface oncofetal proteoglycan highly expressed in various solid tumors, including hepatoblastoma and hepatocellular carcinoma. The therapy is produced by genetically modifying a patient's T cells using a retroviral vector to express a CAR construct derived from the humanized GC33 antibody, which specifically recognizes GPC3. Once infused into the patient—typically following a lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine—these engineered cells are designed to recognize and eliminate GPC3-positive tumor cells. The development of GAP T cells is centered at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine and Texas Children's Hospital, primarily focusing on pediatric patients with relapsed or refractory liver tumors.

Other names

Glypican 3-specific CAR T cellsGlypican3-specific CAR T cellsGlypican-3-specific CAR T cellsGPC3-specific Chimeric Antigen Receptor Expressed in T CellsGPC-3-specific Chimeric Antigen Receptor Expressed in T CellsGPC 3-specific Chimeric Antigen Receptor Expressed in T CellsGlypican-3-specific T cellsGlypican3-specific T cellsGlypican 3-specific T cells